Korczowski Bartosz, Gabinet Lekarski

Rzeszów 35302

10 studies enrolling now · 29 studies all time

What they study most

Arthritis, Juvenile, Arthritis, Psoriatic, Colitis, Ulcerative, Crohn Disease, Crohn's Disease, Crohns Disease, Erosive Esophagitis, Heart Failure, Helicobacter Pylori Infection, Hemophilia A With Inhibitor, Hemophilia B With Inhibitor, Inflammatory Bowel Diseases

Studies at this site

• A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON) — Recruiting now
• A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease — Recruiting now
• Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight — Recruiting now
• Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study — Recruiting now
• A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease — Recruiting now
• A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants — Recruiting now
• A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease — Recruiting now
• A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease — Recruiting now
• A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD) — Recruiting now
• A Study to Evaluate Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects — Recruiting now
• Phase 3 Study to Evaluate the Safety and Efficacy of Hydrocortisone Acetate Suppositories — Completed
• Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis — Running, not enrolling
• A Long-term Extension Study of Ustekinumab in Pediatric Participants — Running, not enrolling
• A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis — Running, not enrolling
• A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease — Completed
• A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation — Running, not enrolling
• A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis — Running, not enrolling
• A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC) — Completed
• A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis — Running, not enrolling
• A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA) — Completed
• Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative Colitis — Completed
• A Study of Mirikizumab (LY3074828) in Participants With Active Crohn's Disease — Completed
• Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Erosive Esophagitis — Completed
• Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Helicobacter Pylori Infection — Completed
• Efficacy and Safety Study of Ontamalimab as Maintenance Treatment in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 307) — Stopped early
• An Efficacy and Safety Study of Ontamalimab as Maintenance Therapy in Participants With Moderate to Severe Ulcerative Colitis — Completed
• Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Hemophilia A or B — Stopped early
• Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative Colitis — Stopped early
• Efficacy and Safety Study of Ontamalimab as Induction Therapy in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 305) — Stopped early